drugset
drugset / Trial / NCT01385566

A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)

NCT01385566 ↗

Phase 1 Completed 223 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupSingle-blindPrevention

Summary

This study will compare the safety and immunogenicity of ZOSTAVAX™ (V211) administered both intradermally and subcutaneously at various doses.

Timeline

Start
2011-09
Primary completion
2013-05
Completion
2013-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Varivax Vaccine 0.1 ml Subcutaneous
Subject Varivax Vaccine 0.15 ml Subcutaneous
Subject Varivax Vaccine 0.22 ml Subcutaneous
Subject Varivax Vaccine 0.65 ml Subcutaneous

Indications

herpes zoster